Collaborations with big biotech and big pharma are on the rise as innovators forge ahead in a challenging economic environment. This growing trend demands creativity and diligent focus on the structure of these agreements to maximize their corporate and product development potential. Panelists will address the following issues and provide case studies that demonstrate how to ensure a successful collaboration:
- Unique arrangement structures at specific product life cycle stages
- Protecting IP
- Avoiding short-term fallout
- The impact of collaboration on future growth and exit strategies
- Strategies from both sides of the agreement: increasing the opportunity for future collaborations
Panelist:
- Richard A. Kaufman, Partner, Foley & Lardner LLP
- David Webb, Vice President, Research & Site Director, Celgene
- David J. Weitz, Senior Vice President, General Counsel and Chief Intellectual Property Counsel, Takeda Pharmaceuticals
- Linda Pullan, Ph.D., Pullan Consulting
Related Insights
10 October 2024
Viewpoints
Proposed Rule Targeting Connected Vehicles Will Impose Major New Supply Chain Compliance Requirements on Automotive Companies that Source from Russia or China
On September 26, 2024, the Department of Commerce’s Bureau of Industry and Security (BIS) published a Notice of Proposed Rulemaking that, if finalized, would prohibit the sale or import of certain automotive hardware and software, as well as “connected vehicles” incorporating this technology, from or linked to the People’s Republic of China or Russia.
11 October 2024
Events
Managing Risk and Driving Resilience | Cybersecurity Summit 2024
On Friday, October 11, Foley Partner Jen Urban will speak on the panel titled, “Managing Risk and Driving Resilience.”
10 October 2024
Manufacturing Industry Advisor
Stellantis Files String of Lawsuits Against UAW Claiming Strike Threats Are Bad Faith
On October 7, 2024, in a coordinated attack, Chrysler owner Stellantis filed a string of lawsuits across multiple jurisdictions against the United Auto Workers Union (“UAW”) and numerous local chapters regarding the UAW’s threats to strike if Stellantis does not move forward with planned investments in its U.S. operations.